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ABSTRACT 
Background Nitroglycerin (also known as glyceryl trinitrate (GTN)), a vasodilator best known for 
treatment of ischemic heart disease, has also been investigated for its potential therapeutic benefit in 
ischemic stroke. The completed Efficacy of Nitric Oxide in Stroke trial suggested that GTN has 
therapeutic benefit with acute (within 6 hours) transdermal systemic sustained release therapy. 
Objective To examine an alternative use of GTN as an acute therapy for ischemic stroke following 
successful recanalization. 
Methods We administered GTN IA following transient middle cerebral artery occlusion in mice. 
Because no standard dose of GTN is available following emergent large vessel occlusion, we performed 
a dose–response (3.12, 6.25, 12.5, and 25 .ig/.iL) analysis. Next, we looked at blood perfusion (flow) 
through the middle cerebral artery using laser Doppler flowmetry. Functional outcomes, including 
forced motor movement rotor rod, were assessed in the 3.12, 6.25, and 12.5 .ig/.iL groups. Histological 
analysis was performed using cresyl violet for infarct volume, and glial fibrillary activating protein 
(GFAP) and NeuN immunohistochemistry for astrocyte activation and mature neuron survival, 
respectively. 
Results Overall, we found that acute post-stroke IA GTN had little effect on vessel dilatation after 15 
min. Functional analysis showed a significant difference between GTN (3.12 and 6.25 .ig/.iL) and 
control at post-stroke day 1. Histological measures showed a significant reduction in infarct volume 
and GFAP immunoreactivity and a significant increase in NeuN. Conclusions These results 
demonstrate that acute IA GTN is neuroprotective in experimental ischemic stroke and warrants 
further study as a potentially new stroke therapy. 
INTRODUCTION 
Stroke, disruption of blood flow to the brain due to vascular occlusion (ischemic) or bleeding (hemor-
rhagic), is the second leading cause of death worldwide and a leading cause of long-term disability.1 
Emergent large vessel occlusion (ELVO) is the most life-threatening and disabling type of ischemic 
stroke. Treatment options for ELVO consist of endovascular thrombectomy (ET) and/or IV tissue 
plasminogen activator (t-PA), but not all patients are eligible owing to exclusion criteria.2–4 
Furthermore, while ET and IV t-PA have improvedpatient survival, there is a need for adjunctive ther-
apies to be used in tandem with or as a standalone treatment following successful vessel recanaliza -
tion.5 Any potential pharmacotherapy administration may be most successful and cause fewer 
systemic side effects if it is targeted at the site of ischemia. We hypothesize that improved treatment 
for ELVO might include rapid recanalization of the occluded vessel via ET combined with directed acute 
pharmacotherapy. To test such a targeted therapeutic approach, our laboratory uses an IA 
experimental model of pharmacotherapy administration in combination with transient tandem ipsi-
lateral common carotid artery (CCA) and middle cerebral artery (MCA) occlusion, hereafter referred 
to as MCA occlusion (MCAo).6 
Using the already exposed vasculature of the MCAo, we can selectively administer our preferred 
drug IA, further mimicking the human clinical condition of pharmacotherapy delivery. Combining the 
two methods allows us to mimic an acute ischemic stroke but also guarantee successful recanalization 
followed by drug delivery in a timely manner similar to ET. Thus far, we have successfully applied this 
experimental therapeutic approach to the administration of verapamil, demonstrating an 86% 
reduction in infarct volume and significant increase in functional outcome.5 These results led us to 
conclude that selectively administering verap-amil IA was safe and neuroprotective. 
In this study, we chose to investigate the therapeutic potential of acute IA administration of nitro-
glycerin (glyceryl trinitrate (GTN)) in our experimental stroke model. GTN is a Food and Drug 
Administration approved vasodilator (angina pectoris, high blood pressure) that was recently studied in 
the Efficacy of Nitric Oxide in Stroke (ENOS) ischemic stroke clinical trial.7–9 That study investigated the 
potential of GTN to reduce blood pressure and improve functional outcome following acute ischemic 
stroke with treatment through a systemic sustained release transdermal patch. Results showed a 
reduction in blood pressure on post-stroke days (PSDs) 1 and 7 but no improvement in functional 
outcome at day 90.7 9 10 Individuals with a stroke are at an increased risk of increased intracranial 
pressure; a reduction in intracranial pressure either through direct (IA) or indirect (patch) administration 
to the cerebrovasculature could improve outcome.11 The ENOS trial acutely reduced blood pressure and 
by doing so it was 
hoped that it would have a neuroprotective effect but it failed to show improvement beyond blood 
pressure reduction. These results could be directly tied to GTN’s short half-life and inability to reach the 
cerebrovasculature if applied as a patch on the arm or chest. 
MATERIAL AND METHODS 
Experiments were performed in accordance with the Institutional Animal Care and Use Committee at the 
University of Kentucky and ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.12 In 
short, 16-week-old C57/Bl6 (25–30 g) male mice (Jackson Laboratories) were given GTN (American 
Reagents) diluted in vehicle (water 39.5%, ethyl alcohol 30%, propylene glycol 30%) or vehicle only IA 5 min 
following transient MCAo. Animals were randomly grouped into naïve (age-matched littermate controls), 
control (MCAo surgery with IA injection of vehicle through the internal carotid artery (ICA)), and treated 
(MCAo surgery with IA injection of 3.12, 6.25, 12.5, 25 and 50 pg/pL GTN through the ICA). Increasing doses 
of GTN were administered to determine safety and efficacy, as there is no standard dose of IA GTN. Previous 
flow rate and injection volume studies determined the optimal flow rate of 2.5 pL/min and injection volume 
of 10 pL per mouse.6 All subjects were treated in a blinded fashion and exclusion criteria were as follows: 
rupture of the MCA/CCA during stroke surgery, inability to place tubing in the external carotid artery (ECA), 
leakage of tubing around the ECA upon pumping, failure of the animal to recover from surgery resulting in 
death, death of the animal during the study, and signs of hemorrhage upon brain extraction (five animals 
were excluded based on these criteria). Our MCAo and IA model of pharmacotherapy administration has a 
mortality rate of <5%.6 
Animal number 
The experiment was conducted using 50 animals (five groups); naïve animals were excluded from laser 
Doppler and MouseOx studies. For laser Doppler and MouseOx (n=5/group), infarct volume 
measurements (n=10/group), functional outcome assessment (n=6/group), blood draws (control n=5, 
treated n=2), and brain immunohistochemistry (n=5/group). 
Vital sign measurements 
Physiological measurements (heart rate (bpm)) and blood pressure (pulse distention (pm)) were taken on 
animals undergoing only the IA surgery (no MCAo surgery) over a 20 min period, beginning at the IA 
injection and continuous through 20 min. Measurements were taken using the MouseOx Plus (Starr Life 
Science), where a thigh sensor was placed on the shaved left thigh of an anesthetized mouse. 
Perfusion 
Blood flow through the MCA was measured using the laser Doppler Periflux System 5000 with a 2 mm tip 
(Perimed). Blood flow measurements were taken before and after occlusion and 15 min after IA injection 
(IA injection occurs following reperfusion). 
Middle cerebral artery occlusion and intra-arterial injection Animals were anesthetized using a 
ketamine/xylazine mixture for the MCAo and IA injection procedure. Transient focal cerebral ischemia was 
induced using our previously described method.5 6 13 14 MCAo occlusion was for 1 hour with pre-/ post-
occlusion and recanalization confirmed by laser Doppler flowmetry. Body temperature was measured 
using theMouseOx Plus (rectal thermometer) and maintained with a heating pad. GTN IA injection 
followed our previously published proto-col.5 6 In brief, a midline incision was made from mandible to 
sternum exposing and isolating the CCA, ECA, and ICA. The ECA was permanently occluded with suture at 
its distal end and the ICA was temporarily occluded. Using a pair of micro-scissors, a small nick was made 
in the ECA midway between the CCA bifurcation and the proximal suture. Micro-angio tubing was inserted 
into the ECA through the nick and placed at the bifurcation and suture was used to secure the tubing into 
the ECA. After removing occlusion of the MCA, CCA and ICA flow was restored and the vessel was allowed 
to recanalize for 5 min. At that time, GTN or vehicle was injected via the IA route.5 6 Once the injection 
was complete the ECA was permanently occluded at its proximal end with a third suture and the animal 
was sutured closed. 
Behavioral testing 
Animals were subjected to rotor rod to determine functional ability following surgery and 
pharmacotherapy administration. Animals were trained for 3 days before stroke surgery and tested 3 days 
following stroke surgery. Rotor rod was used to determine the percentage change from baseline over a 5 
min interval with an accelerating rod from 0 to 40 rpm for three trials. 
Infarct volume 
On PSD 7 mice were euthanized via cervical dislocation, the whole brain was removed and flash frozen, 
sectioned on a cryostat (20 pm), and stained using cresyl violet. Infarct volume was analyzed from scanned 
cresyl violet sections with Image J software (NIH).5 
Blood draws 
To measure nitric oxide (NOx) levels in the blood, submandibu-lar blood draws were performed 1 day 
before stroke (baseline), 15 min after IA injection, and PSD 1. In short, animals were placed in the dorsal 
position with their head tilted exposing the submandibular vein region.15 A 5 mm Goldenrod animal lancet 
was used to pierce the submandibular vein, blood (10% of the total animal blood volume) was collected 
into K2-EDTA tube, and centrifuged at 14 000 rpm for 15 min. Plasma was collected and analyzed for NOx 
levels. 
NOx analysis 
Nitrate reductase was used to reduce nitrate to nitrite in blood plasma samples. A volume of 5 pL nitrate 
reductase and 5 pL of co-factor (Nitrite/Nitrate Assay Kit, Sigma-Aldrich, UK) was added to 40 pL plasma 
and incubated for 2 hours at 25°C. Nitrate/nitrite (NOx) concentrations were then determined using 
Sievers Nitric Oxide Analyzer (NOA 280i; GE Instruments, UK). During this procedure the nitrite was 
reduced to nitric oxide by acetic acid. Nitric oxide was then quantified using ozone-chemiluminescence 
technology. 
Immunohistochemistry 
Whole brains flash frozen were sectioned on a cryostat (Leica) at 20 pm and mounted on slides. Glial 
fibrillary activating protein (GFAP 1:500 antibody dilution, Sigma) immunohisto-chemistry was used to 
evaluate astrogliosis, and NeuN (1:500 antibody dilution, Abcam) immunohistochemistry was used to 
analyze mature neuron survival in the stroke-affected region (core and penumbra). Infarct and peri-
infarct regions (defined as a 500 pm boundary extending from the edge of the infarct 
 
core, medial and lateral to the infarct) of the cortex were identified histologically after cryostat sectioning. 
Stains were imaged with a Nikon Eclipse Ti microscope and images collected with a charge coupled device 
(CCD) camera and Nikon NIS Element BR software. Photoshop software was used to analyze positive pixel 
density of sectioned brains from naïve, control, and treated groups. 
Statistical analysis 
Measured variables are shown as mean±SEM. Analysis of results for comparison between treatment groups 
(infarct volume, immunohistochemistry) was performed using Student’s t test. Time course comparisons 
(behavior) and NOx were analyzed using a two-way repeated measures analysis of variance. We defined 
significance as *p<0.05, **p<0.01, and ***p<0.001. 
Compliance with STAIR criteria 
To maximize the applicability of our results, we designed the study with reference to the Stroke Treatment 
Academic Industry Roundtable (STAIR) recommendations for preclinical neuropro-tection research.16 We 
also performed a dose–response study to determine if there was a deleterious dose, and found that all 
animals survived IA GTN injections. 
RESULTS 
Vital sign measurements 
Physiological measurements for heart rate (IA injection only) demonstrated no difference from baseline 
for all groups except the 6.25 µg/µL GTN group, which showed a significant reduction in beats per minute 
from immediately after IA to 15 min after IA, though these animals recovered without incident despite a 
lowered heart rate. Pulse distention showed no difference between groups from baseline with all animals 
recovering without incident. Data not shown. 
Perfusion 
Perfusion measurements using the laser Doppler were made at baseline, occlusion, and 15 min after IA to 
determine whether IA GTN had any effect on the MCA perfusion. We demonstrated an 83% reduction in 
cortical blood flow through the MCA after occlusion. After removal of the occlusion and 5 min 
recanalization, GTN and vehicle were administered IA and blood flow was measured 15 min after IA. While 
all groups increased perfusion through the MCA there was no significant difference between GTN doses 
and vehicle over the time period analyzed (figure 1A). 
 
Infarct volume 
Infarct volume (figure 1B) was assessed using cresyl violet (figure 1C) and analyzed on PSD 7 using Image 
J. Mean infarct volumes (mm3) demonstrated a dose–response effect compared with control, with 12.5 
µg/µL GTN showing a significant decrease in infarct volume. However, the 25 µg/µL dose showed signs 
of hemorrhage and an infarct volume similar to control. 
Behavioral testing 
In addition to infarct volume assessment, we performed rotor rod functional analysis on all of the groups 
except the less well-tolerated 25 µg/µL dose. Functional assessment of IA GTN on the rotor rod was 
measured as the percentage change from baseline on PSDs 1, 3, and 7 (figure 2). On PSD 1 the control 
stroke group showed a decrease from baseline (−27.25±13.42) as expected with injury, while the naïve 
group without any brain injury continued to improve on the task (21.10±31.43) as expected. GTN doses of 
3.12 and 6.25 µg/µL showed a significant improvement (23.48±35.30 and 30.51±25.06, respectively) 
compared with control, while the 12.5 µg/µL GTN dose was only slightly less than baseline (−7.36±24.52). 
On PSD 3, the control group was still reduced from baseline (−12.65 ±32.51) and the GTN dose of 
3.12µg/µL (20.75±19.04) remained above baseline but was slightly less than PSD 1 measurements. GTN 
group 6.25 µg/µL (36.73±27.2) continued to improve from baseline and PSD 1 measurements, and 12.5 
µg/µL (51.77±32.29) improved significantly from PSD 1 measurements. On PSD 7, the control group 
remained below baseline levels (−26.11±26.88). However, the GTN dose of 3.12 µg/µL (10.51±22.91) 
remained above baseline measurements but was slightly less than its PSD 1 and 3 measurements and the 
6.25 µg/µL (35.59±26.63) and 12.5 µg/µL (32.34 ±37.79) GTN doses continued to improve from baseline 
and their PSD 1 values. Nevertheless, none of the GTN dose measurements were significantly greater than 
the control by PSD 7. 
Blood nitric oxide measurements 
As one of the goals of the IA administration of GTN after stroke was to limit systemic effects, we 
investigated whether such IA GTN administration had any effect on blood NOx levels. Compared with 
baseline, blood NOx levels were elevated 15 min after either IA injection or GTN treatment, the latter being 
slightly, but not significantly, more elevated. By PSD 1, blood NOx remained similarly elevated from 
baseline levels in both groups (figure 3). 
 
 Immunohistochemistry 
Antibodies specific to proteins associated with mature neuron survival (NeuN) and astrocytic activation 
(GFAP) were used (figure 4). Compared with control, GTN treated animals showed a dose–response 
stair step effect with a significant increase in NeuN positive pixels at doses 3.12, 6.25, and 12.5 pg/pL. 
Likewise, a similar stair step dose–response was seen in GFAP, with control having a significantly 
increased number of GFAP positive pixels compared with GTN doses 6.25 and 12.5 pg/pL. 
DISCUSSION 
Currently, IV t-PA is the only approved pharmacotherapy available but extensive exclusion criteria limit its 
use to less than 16% of those affected by stroke. With the recently completed and successful ET trials for 
ELVO, ET can be used to rapidly recanalize stroke through IA access. This provides a clinical/ translational 
opportunity to co-administer potentially neuropro-tective compounds. Using a clinically relevant mouse 
model of stroke (MCAo), we have developed a new method of IA (similar to ET) pharmacotherapy delivery 
that allows us to deliver a selected compound directly to the site of ischemia while mitigating systemic 
side effects.5 
GTN was used in the recently completed ENOS trial and shown to be safe when administered in patch 
form following stroke. The outcome of the trial was an acute reduction in blood pressure, but no 
improvement in functional outcome.9–11 GTN is a known vasodilator and is commonly used to treat 
ischemic heart disease, but we and others believe it may also have significant neuroprotective properties 
as discussed below. Therefore, our goal in this study was to target GTN directly at the site of the stroke via 
our IA model following MCAo to evaluate these potentially neuroprotective properties. 
Since no standard IA dose of GTN is available we started with a dose–response evaluation (3.12, 6.25, 
12.5, and 25 pg/pL) to determine if IA GTN was safe (no bleeding into the parenchyma) and had an effect 
on infarct volume. Our study showed that the mice tolerated and survived IA GTN with no overt deleterious 
effects, and there was a positive dose-dependent effect on infarct volume with a significant reduction noted 
with the 
12.5 µg/µL dose. However, the 25 µg/µL dose resulted in bleeding into the ventricles and an infarct 
volume similar to control. Therefore, we conclude that IA GTN is a potentially safe neurotherapeutic 
with a specific toxicity profile, which includes intraventricular hemorrhage at the highest dose tested. 
Additional studies should further delineate the most effective dose.  
We evaluated the potential effect of IA GTN on functional outcome. Although the lower doses (3.12 and 
6.25 µg/µL) initially had significant positive effects immediately following infarct induction on PSD 1, 
dose–response effects were no longer observed by PSD 7 (though functional outcome was still improved 
compared with controls). This may be due, in part, to GTN’s very short half-life (1.5–7.5 min) such that 
noted beneficial effects on infarct volume and neuronal viability (and decreased reactive gliosis) were 
not sufficiently pervasive to result in long-term functional benefit. In further support of such a conclusion, 
one potential mediator of GTN neuroprotection, NOx (discussed elsewhere in greater detail17–19 and 
below), also has an extremely short half-life of 2–6 s. We expect that further studies with post-stroke IA 
GTN, or perhaps combining IA GTN with other longer lasting potentially neuroprotective agents using 
multiple assessment tools, may demonstrate functional benefits. 
Although we saw no effects of IA GTN on animal pulse distention, we further examined potential systemic 
effects from IA GTN administration by measuring post-stroke blood NOx levels at several points after IA 
GTN or vehicle administration. NOx is a good measure of IA GTN administration because GTN is converted 
to NOx by endothelial nitric oxide synthetase and released into the blood stream from the vascular 
endothelium. Ultimately, we noted a transient, but insignificant increase in blood NOx levels with IA GTN 
treatment. These results are consistent with efficacious GTN delivery and suggest a potential mechanism 
of action, while simultaneously further demonstrating a relative lack of systemic effects with IA GTN 
treatment. 
It has been known for decades that GTN has both neuropro-tective and neurotoxic properties, depending 
upon whether it is present in physiologic or pathologic concentrations, respectively. Post-stroke GTN-
mediated neuroprotection may result from vasodilatation of the effected vasculature, which leads to 
increased blood flow and return of nutrients. NOx has been shown to be neuroprotective through vessel 
dilatation, anti-apoptotic mechanisms as a reactive oxygen species scavenger, and through inhibition of 
lipid peroxidation sustaining cellular membrane integrity. In our study, we noted transient, but insig-
nificant increases in both MCA vasodilatation and blood NOx levels with IA GTN treatment. The mechanism 
of action of IA GTN may be a combined effect (vasodilatation and production of nitric oxide species), but 
one additional possibility is that IA GTN might have increased local NOx levels in the stroke-targeted brain; 
this analysis should be performed in additional studies. Collectively, despite the limitations of this study, 
our results suggest a new therapeutic modality of GTN which, independent of its blood-pressure-lowering 
effects, might be of benefit after ischemic stroke. 
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 Figure 1 (A) Blood perfusion measurements as percentage change from baseline for combined 
groups (black dot), control (red line), 3.12 µg/µL (green line), 6.25 µg/µL (gray line), and 12.5 µg/µL 
(blue line) at baseline (0–5 min), post-occlusion (5 min after occlusion), and post-IA injection (15 
min after IA injection). Combined (N=30), control (n=5), 3.12 µg/µL (n=5), 6.25 µg/µL (n=5), and 
12.5 µg/µL (n=5). (B) Infarct volume analysis of control versus GTN doses (3.12, 6.25, 12.5, and 25 
µg/µL). (C) Cresyl violet image for control, 3.12 µg/µL, 6.25 µg/µL, 12.5 µg/µL, and 25 µg/µL group 
(n=10 per group). *p<0.05; **p<0.001. GTN, glyceryl trinitrate. 
 
 
Figure 2 Rotor rod behavioral measurements: control (black), naïve (red), 3.12 pg/pL (green), 6.25 
pg/pL (gray), and 12.5 pg/pL (blue). Rotor rod forced motor movement percentage change from 
baseline; groups were trained and combined for baseline measurements. Groups were separated 
after stroke surgery into control, naïve, and GTN treated and were tested on PSD 1, 3, and 7 (n=6 per 
group). */#p<0.05. GTN, glyceryl trinitrate; PSD, post-stroke day. 
 
Figure 3 Nitric oxide (NOx) blood concentrations for control versus GTN (12.5 pg/pL) treated on post-IA 
and day 1. Treated (n=2), control (n=5). GTN, glyceryl trinitrate. 
 
 Figure 4 Graphs and images for immunohistochemistry, magnification at 20× with quantification of 
positive pixel density. (A) Graph depicting positive pixel for GFAP control versus GTN-treated doses in 
infarcted region with representative images. (B) Graph depicting positive pixels for NeuN stain for 
control versus GTN treated doses in infarcted region with representative images (n=5 per group). Scale 
bar=100 μm. *p<0.05; **p<0.001; ***p<0.0001. GFAP, glial fibrillary activating protein; GTN, glyceryl 
trinitrate. 
 
